CytoMed Therapeutics Limited (GDTC)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SGD m | 0 | 0 | 0 | 1 | 0 | 0 | 1 | - |
| Operating profit | SGD m | -5 | -4 | ||||||
| Net profit | SGD m | -2 | -2 | -3 | -4 | -3 | -4 | -5 | - |
| EPS reported | SGD | -0.33 | -0.40 | ||||||
| Operating cashflow per share | SGD | -0.32 | -0.46 | ||||||
| Capex per share | SGD | 0.06 | 0.08 | ||||||
| FCF per share | SGD | -0.38 | -0.54 | ||||||
| Free cash flow | SGD m | -4 | -6 | ||||||
| Net debt | SGD m | -2 | -2 | ||||||
| Book value equity | SGD m | 7 | 7 | ||||||
| Book value per share | SGD | 0.56 | 0.56 | ||||||
| Number of shares | m | 11.65 | 11.79 | ||||||
| DPS (TTM paid) | SGD | 0.00 | 0.00 |
Financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.07 | 3.07 | ||||||
| P/S LTM | x | 62.86 | 31.22 | ||||||
| P/FCF LTM | x | -4.56 | -3.17 | ||||||
| EV/EBITDA LTM | x | -4.29 | -3.50 | ||||||
| EV/Sales LTM | x | 57.81 | 19.83 | ||||||
| Earnings Yield LTM | % | -19.52% | -33.90% | ||||||
| FCF Yield | % | -21.93% | -31.58% | ||||||
| Quality | |||||||||
| ROE | % | -59.85% | -70.74% | ||||||
| ROIC | % | -61.61% | -58.88% | ||||||
| Operating margin | % | -14.16% | -6.72% | ||||||
| Gross margin | % | -2.78% | -20.48% | ||||||
| FCF/Sales | % | -1378.6% | -986.02% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +359.28% | +824.65% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -9.12 | -13.13 | ||||||
| Net Debt/EBITDA | x | 0.38 | 0.31 | ||||||
| EBIT/Net interest | x | -219.72 | -209.99 | ||||||
| Net debt/market cap | % | +2.04% | +2.85% | ||||||
| Net debt/Equity | x | -0.26 | -0.26 | ||||||
| Gross debt/equity | x | 0.07 | 0.07 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
CytoMed Therapeutics Limited (GDTC)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free